-
bioAffinity Technologies receives Australian patent acceptance
-
bioAffinity Technologies receives US patent allowance for lung cancer test
-
bioAffinity Technologies closes $1.8 million stock offering
-
bioAffinity Technologies raises $1.8 million in registered direct offering
-
bioAffinity Technologies raises $1.8 million in registered direct offering
-
bioAffinity reports 95% quarterly jump in lung cancer test sales
-
bioAffinity shares case studies showing CyPath Lung test detected stage 1A cancer
-
bioAffinity (BIAF) files for 32.5M share offering by selling stockholders
-
bioAffinity (BIAF) files for 12.61M share offering by selling stockholders
-
bioAffinity Technologies, Inc. (BIAF) Misses Q2 EPS by 7c
-
bioAffinity Technologies receives Canadian patent for lung cancer test
-
bioAffinity Technologies receives China patent for lung cancer diagnostic
-
bioAffinity (BIAF) receives patent grant from CNIPA
-
bioAffinity (BIAF) Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
-
bioAffinity (BIAF) Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
-
bioAffinity Technologies, Inc. (BIAF) Tops Q1 EPS by 1c
-
bioAffinity (BIAF) Closes $3.25M Offering
-
bioAffinity (BIAF) Prices $3.25M Share Offering at $0.32/sh
-
bioAffinity (BIAF) Increases Efficiency of CyPath Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
-
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
bioAffinity (BIAF) Reports Record $9.4M Revenue for 2024
-
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
bioAffinity (BIAF) Announces Targeted Actions to Cut $4M in Costs
-
bioAffinity (BIAF) Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
-
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
bioAffinity (BIAF) Appoints William Bauta as Chief Science Officer
-
bioAffinity (BIAF) receives Japanese Patent for CyPath Lung
-
bioAffinity (BIAF) Prices 2.05M Share Offering at $1.30/sh
-
bioAffinity's (BIAF) CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
-
bioAffinity (BIAF) Names J. Michael Edwards as Chief Financial Officer
-
bioAffinity (BIAF) Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test
-
bioAffinity (BIAF) Announces $1.75M Offering at $1.50/sh
-
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
bioAffinity (BIAF) Reports 217% Sales Growth in Second Quarter 2024 for CyPath Lung
-
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

